Summary
UCB Ventures is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €213.8m and a net result of €65.8m. Equity is growing by about 31% per year across the filed financial years. Its solvency ranks better than 95% of 3,016 sector peers (NACE 64, financial year 2025). The company has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals.
Group and network
Holdings and subsidiaries
15 holdingsHoldings 15
- UCB Ventures BelgiumsubsidiaryEquity €28.7mResult €1.9m99.99%
-
36%
- Rinri Therapeutics Ltd.GBSourceown accounts 202524.98%
- Vianautis Bio LimitedGBSourceown accounts 202517.52%
- Switch Therapeutics Inc.USSourceown accounts 202516.47%
- Cenos Therapeutics Inc.USSourceown accounts 202514.84%
- SpliceBio S.L.ESSourceown accounts 202514.3%
- Iris Medicine IncUSSourceown accounts 202512.25%
- StrideBio, incUSSourceown accounts 202511.44%
- Walden Biosciences Inc.USSourceown accounts 202511.35%
Show 5 more holdings
- Locanabio Inc.USSourceown accounts 20256.56%
- RTW Biotech Opportunities LtdGBSourceown accounts 20256.1%
-
3.19%
- Code Biotherapeutics Inc.USSourceown accounts 20252.58%
- Neurona Therapeutics Inc.USSourceown accounts 20252.42%
According to the 2025 annual accounts of UCB Ventures and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Connections & network
2 current directorsThe network starts from this company’s directors. Other companies they run appear here as nodes.